Danaher subsidiaries Beckman Coulter, Cepheid, and Leica Biosystems will be working together with external partners to focus on existing disease areas.

The company reported 5 percent growth in Europe and 3 percent growth in North America, while its revenues in the rest of the world dipped 2 percent.

The development marks a shift up the value chain for labs and could prove a meaningful revenue stream for providers able to ...

China's volume-based procurement policy and US tariffs have forced companies with large business in China to reset their ...

Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the value of their ...

Diagnostics revenue totaled €1.06 billion in Q3 compared to €1.11 billion a year ago, down 4 percent or a fraction of a percent on an adjusted basis.

The 15-minute digital lateral flow immunoassay originally obtained Emergency Use Authorization from the US FDA in 2020.

The funding supports development of an assay to detect and differentiate H5 influenza A from seasonal H1 and H3 subtypes, flu B, and COVID-19.

The funding supports development of an assay to detect and differentiate H5 influenza A from seasonal H1 and H3 subtypes, flu B, and COVID-19.

The company's platform combines microfluidics, cytology, and artificial intelligence-based image analysis for the identification of mild-to-severe dysplasia.

Breaking news on diagnostics business, policy, and funding. Real-time updates on clinical labs and the in vitro diagnostics market from 360Dx.

The Uppsala University spinout aims to use its SuperRCA mutation detection technology for applications including molecular residual disease monitoring.